U.S. Property Rights Maintain Global Rank

The 2014 International Property Rights Index (IPRI), published by the Property Rights Alliance, ranks the United States 17th place overall in the world (from 17th in 2013 and 18th in 2011 and 2012). The IPRI is an annual comparative study that quantifies the strength of physical and intellectual property rights and ranks countries accordingly. The U.S. improved its legal and political environment from 2013 to 2014 via marginal improvements in control of corruption, judicial independence, and political stability. Its physical property rights score improved due to increases in the country’s access to loans and real estate. Likewise, the U.S. intellectual property rights score increased due to improvements in the country’s copyright piracy score.

The NCPA has emphasized the importance of intellectual property protection in health care and this blog has written about how pharmaceutical innovation in today’s regulatory environment could not be financed without patent protection. According to the IPRI, such dynamics exist globally between many macro indicators: with each annual edition of the index, statistical strength between economic production and protection of property rights has grown.


Source: IPRI Index Composition and Coverage, The International Property Rights Index 2014.

Protected physical and intellectual property rights boost innovation and lead to economic growth. In an increasingly regulated global economy, it is imperative that the U.S. continue to respect property rights.

Comments (3)

Trackback URL | Comments RSS Feed

  1. Jake Sanders says:

    I sure hope America cracks the top ten soon

  2. Santiago says:

    It may be necessary for special considerations to be made for more inelastic goods… Market power granted by patents can easily become a problem for fellow producers and competitors. If an innovative first-mover firm can capitalize on that disadvantage, it may become costly for the consumer as well…

    • Jeong Seo says:

      Referring to the pharmaceutical industry, regulatory burden makes R&D very expensive and investment in said R&D would not occur without patent protection.